Pricing and access
Biosimilars and interchangeable biologics, and how to find them
Biosimilar database guide: what biosimilars and interchangeable biosimilars are, how substitution works, and how to find them in FDA's Purple Book for free.
By the All In Biotech editorial team · Published November 18, 2026 · 6 min read
A biosimilar is a biologic that FDA has found highly similar to an already licensed biologic, called the reference product, with no clinically meaningful differences in safety, purity and potency. An interchangeable biosimilar has met additional requirements, so a pharmacist may substitute it for the reference product without asking the prescriber, where state law permits. FDA's Purple Book is the free official database of both.
This post explains the legal pathway, what the interchangeable designation does and does not mean, where FDA's policy on switching studies stands, and how to look up biosimilars and their Medicare spending.
The legal pathway: section 351(k)
Biologics are licensed under section 351 of the Public Health Service Act. An original biologic goes through a full Biologics License Application under section 351(a). The Biologics Price Competition and Innovation Act of 2009 added an abbreviated route, section 351(k), for products that are biosimilar to, or interchangeable with, a licensed reference product.
Under the statute, biosimilar means the product is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and there are no clinically meaningful differences between the two in safety, purity and potency. FDA's biosimilars review and approval page describes the evidence: mostly detailed analytical comparison of structure and function, plus clinical pharmacology data and other studies as needed.
Biosimilars are not generics. A generic small-molecule drug has the same active ingredient as its brand. A biologic is a large, complex molecule made in living cells, and two manufacturers cannot make identical copies. That is why the standard is "highly similar" and why the approval route is separate. For how this compares with NDAs and ANDAs, see NDA vs BLA vs ANDA.
Naming
FDA's naming policy gives each biologic a core name followed by a four-letter suffix with no meaning, for example adalimumab-atto or insulin glargine-yfgn. The suffix distinguishes products from different manufacturers that share a core name. It helps with tracking in prescribing records and adverse event reports.
What interchangeable means
An interchangeable biosimilar must meet the biosimilarity standard and two further conditions in the statute:
- it can be expected to produce the same clinical result as the reference product in any given patient; and
- for a product given more than once, the risk in terms of safety or reduced efficacy of alternating or switching between it and the reference product is not greater than the risk of using the reference product without switching.
The practical effect is in the statute's definition of interchangeability: the product may be substituted for the reference product without the intervention of the prescribing health care provider.
Interchangeable does not mean "better" or "more similar" in a clinical sense. FDA states that biosimilars and interchangeable biosimilars meet the same high standards for approval, and that a patient can expect the same safety and effectiveness from either. The designation is about pharmacy-level substitution.
Substitution is governed by state law
FDA decides whether a product is interchangeable. Whether a pharmacist actually substitutes it is decided by state pharmacy law. States have passed laws on biologic substitution that differ in their details, for example on whether the pharmacist must notify the prescriber, keep particular records or inform the patient, and on how a prescriber can block substitution.
So the same interchangeable product can be handled differently from one state to the next. A biosimilar without the interchangeable designation can still be prescribed by name, and payers can prefer it on a formulary, but pharmacy-level substitution without the prescriber generally requires the designation.
FDA's evolving position on switching studies
For several years FDA's guidance generally expected a switching study to support interchangeability: a trial in which patients alternate between the reference product and the proposed interchangeable product.
That position has changed. In June 2024 FDA issued a draft update to its interchangeability guidance saying that switching studies are generally not needed, and that applicants can instead explain why their analytical and clinical data support the interchangeability standard. In October 2025 FDA issued further draft guidance saying comparative efficacy studies may often not be needed to show biosimilarity. FDA leadership has said it intends to finalize these guidances.
As of this writing, the June 2024 interchangeability guidance remains in draft form as far as we could confirm. Guidance status changes, and Congress has also considered bills that would change the interchangeability standard. Check FDA's guidance documents search for the current version before relying on any of this.
Exclusivity: 12 years for the reference product
The BPCI Act gives a reference biologic 12 years of exclusivity from the date of its first licensure. FDA cannot make a 351(k) approval effective until that period ends. A biosimilar application also cannot be submitted until 4 years after the reference product's first licensure.
The first biosimilar found interchangeable with a given reference product can also receive a period of first interchangeable exclusivity, during which FDA cannot find a later biosimilar interchangeable with the same reference product. The length depends on statutory triggers such as the product's commercial launch and patent litigation.
Patents are separate from exclusivity. Biologic patent disputes follow their own process under the BPCI Act, and the Purple Book now includes some patent information submitted under it. For how this compares with small-molecule drugs, see Orange Book vs Purple Book.
How to find biosimilars
The Purple Book
The Purple Book is FDA's database of licensed biological products. For each product it shows:
- the proprietary and proper names, BLA number and sponsor;
- the license type, such as 351(a) for reference products and 351(k) for biosimilars;
- whether a 351(k) product is biosimilar or interchangeable, and with which reference product;
- the dates of licensure and any reference product exclusivity expiry;
- marketing status.
Search by the reference product's name to see every biosimilar licensed against it. FDA also keeps a biosimilar product information page listing approved biosimilars.
This site's drug pages
All In Biotech does not hold Purple Book data of its own. Its catalog is built from Drugs@FDA, which as of November 2026 includes 487 BLAs for biologics regulated by CDER, alongside 5,412 NDAs. Many therapeutic biologics, including monoclonal antibodies and, since March 2020, insulins, sit in that catalog. Vaccines, blood products and most cell and gene therapies are regulated by CBER and are not.
Use the drug pages for approval history, labels, recalls and safety reports, and use the Purple Book for biosimilar and interchangeable status.
Biosimilars and Medicare spending
Many large biologics are given in clinics and paid under Medicare Part B, which is where biosimilar competition shows up first in spending data. In CMS's 2024 Part B Spending by Drug data, gross of rebates, the top drugs included Keytruda at $5.99 billion, Prolia at $2.43 billion and Eylea at $2.37 billion. Prolia's ingredient denosumab and Eylea's ingredient aflibercept both have biosimilars listed in the Purple Book, so those rows are worth tracking in later data years.
Part B generally pays for a biosimilar at its own average sales price plus 6 percent of the reference product's average sales price. The Inflation Reduction Act temporarily raised that add-on to 8 percent for qualifying biosimilars. CMS's Medicare Part B drug pages explain the current rules.
Self-administered biologics are mostly paid under Part D. In 2024 Part D data, the Humira pen had $4.33 billion in gross spending, even though several adalimumab biosimilars were on the market. Part D figures are gross of manufacturer rebates, so they overstate net cost, and rebates often matter a great deal for biologics. For how to read these datasets, see how much Medicare spends on a drug.
Summary of the terms
| Term | Meaning |
|---|---|
| Reference product | The original biologic licensed under 351(a) that a biosimilar is compared against |
| Biosimilar | Licensed under 351(k), highly similar, no clinically meaningful differences |
| Interchangeable biosimilar | Biosimilar that meets the extra statutory standard and may be substituted without the prescriber, subject to state law |
| Reference product exclusivity | 12 years from first licensure of the reference product |
| Purple Book | FDA's database of licensed biologics, biosimilars and interchangeables |
Whether to use a particular biosimilar is a decision for prescribers, pharmacists and payers. The public data shows what is licensed, how it is designated and what Medicare spends.
Frequently asked questions
- What is a biosimilar?
- A biosimilar is a biological product licensed under section 351(k) of the Public Health Service Act that is highly similar to an FDA-licensed reference product and has no clinically meaningful differences in safety, purity and potency.
- What does interchangeable mean for a biosimilar?
- An interchangeable biosimilar meets additional requirements and may be substituted for the reference product at the pharmacy without the prescriber's intervention, where state law allows.
- Where can I find a list of biosimilars?
- FDA's Purple Book at purplebooksearch.fda.gov lists licensed biological products, their biosimilars and interchangeable designations, and reference product exclusivity.
- How long is reference product exclusivity?
- A reference biologic has 12 years of exclusivity from its first licensure before FDA can make a biosimilar approval effective.
For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.